Skip to Content
  1. All products
  2. Blends & Stacks
  3. KLOW (GHK-CU/TB-500/BPC-157/KPV)
  4. Blends & Stacks
Pricelist: - Pricelist
Pricelist: - Pricelist
KLOW (GHK-CU/TB-500/BPC-157/KPV)

KLOW (GHK-CU/TB-500/BPC-157/KPV)

Blend · Subcutaneous Store refrigerated at 2-8 C and protect from heat and light. 99% Purity · USP Grade
99% Purity
PHYSICIAN USE ONLY
Format
⚗ blend
  • Strength
Clinical Description

Recovery support blend for advanced tissue repair, skin barrier recovery, and inflammatory balance.

KLOW (GHK-CU/TB-500/BPC-157/KPV) is part of the Mital clinical catalog as a stack-focused entry with standardized preparation, dosing, and quality-control guidance.

Clinical Indications
Post-procedure recovery protocolsConnective tissue and skin repair supportInflammation and healing pathway support
Recommended Stacking Protocols
✓
Recovery & Tissue Repair Base
Core recovery & tissue repair support for consistent outcomes.
✓
Adjunct Support
Complementary recovery & tissue repair pathway when indicated.
Blend Components
Component Amount (mg)
GHK-CU 6.25
TB-500 1.25
BPC-157 1.25
KPV 1.25

Mechanism of Action - Recovery & Tissue Repair Pathway

A
Targeted Signaling
Supports protocol objectives for KLOW (GHK-CU/TB-500/BPC-157/KPV).
B
Clinical Modulation
Allows dose and schedule adjustments by response.
C
Outcome Tracking
Pairs with clinician monitoring for iterative optimization.
Starting Dose
Low initial dose
Initiation phase for tolerance and baseline response.
Titration
Escalate by protocol
Maintenance Range
Maintain physician-directed target
Adjust based on objective outcomes and physician review.
Suggested Dosing Notes

Use physician-guided initiation, titration, and maintenance phases aligned with response, tolerability, and objective biomarkers.

Period Dose Phase Clinical Notes
Weeks 1-2 Initial phase initiation Begin conservatively and monitor tolerance.
Weeks 3-6 Escalation phase escalation Increase per protocol if tolerated.
Week 7+ Maintenance phase maintenance Maintain target dose and reassess monthly.
Preparation Protocol

Reconstitute with bacteriostatic water using aseptic handling. Inject diluent slowly along the vial wall and swirl gently until fully dissolved.

1
Inspect vial
Confirm vial integrity, lot, and expiration before use.
2
Aseptic reconstitution
Disinfect stopper and add bacteriostatic water slowly.
3
Gentle dissolution
Swirl gently until the solution is clear and homogeneous.
4
Prepare dose
Draw dose according to reconstitution conversion guidance.
Reconstitution & Dosing Guide
Standard 1 mL insulin syringe: 100 units = 1 mL

Total Peptide: 10 mg
BW: 2 mL
Concentration: 50/10/10/10 mg/mL
Dose Units to Draw Volume (mL) Approx. Supply
Half protocol dose 50 1.00 4 injections
Full protocol dose 100 2.00 2 injections
Identity
  • Product Name: KLOW (GHK-CU/TB-500/BPC-157/KPV)
  • Strength Options: 50/10/10/10 mg
Quality & Purity
  • Purity: >= 99%
  • Sterility: Aseptic handling required
Storage & Handling
  • Storage: 2-8 C refrigerated
  • Handling: Avoid heat, shaking, and direct light

Timing: Use consistent administration timing for stable protocol tracking.

Storage: Store refrigerated at 2-8 C and protect from heat and light.

Frequency: Frequency follows protocol phase and physician direction.

Cycle: Cycle length and cadence are clinician-defined per patient profile.

Injection Sites: Rotate approved injection sites to reduce local irritation risk.